Bioequivalence of Tolvaptan OD vs Conventional Tablets

Phase 1, randomised, open-label trial of tolvaptan in hyponatremia and autosomal dominant polycystic kidney disease (ADPKD) (6 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 16 hours and Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at 16 hours. Started Jan 2017; status: completed.